Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Increasing Doses of CBTDs on Cystine Capacity
NCT02125721Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Jun 2012
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tiopronin and penicillamine in cystinuria (CSNU), sponsored by NYU Langone Health. Primary endpoint: Urinary Cystine Capacity. Started Jun 2012; status: completed.
02
Drugs
tioproninpenicillamine
03
Conditions
cystinuria (CSNU)
Beyond the preview
Go deeper on NCT02125721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125721.